Delayed switch of antiretroviral therapy after virologic failure associated with elevated mortality among HIV-infected adults in Africa

AIDS

Volumn 28, Issue 14, 2014, Pages 2097-2107

  Petersen, Maya L ^a   Tran, Linh ^a   Geng, Elvin H ^b   Reynolds, Steven J ^c,d,e   Kambugu, Andrew ^f   Wood, Robin ^g   Bangsberg, David R ^h,i   Yiannoutsos, Constantin T ^j   Deeks, Steven G ^b   Martin, Jeffrey N ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c RAKAI HEALTH SCIENCES PROGRAM   (Uganda)

^d NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f Infectious Diseases Institute   (Uganda)

^g UNIVERSITY OF CAPE TOWN   (South Africa)

^h MBARARA UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Uganda)

ⁱ HARVARD MEDICAL SCHOOL   (United States)

^j INDIANA UNIVERSITY   (United States)

more..

Author keywords

Antiretroviral; Cohort studies; HIV; HIV RNA level; Inverse probability weight; Marginal structural model; Time dependent confounding; Treatment failure; Viral load

Indexed keywords

ANTIRETROVIRUS AGENT; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; VIRUS RNA; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; AFRICA; ARTICLE; DRUG TREATMENT FAILURE; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PATIENT MONITORING; PRIORITY JOURNAL; SOUTH AFRICA; UGANDA; CD4+ T LYMPHOCYTE; CLINICAL TRIAL; COHORT ANALYSIS; DRUG ADMINISTRATION; DRUG EFFECTS; EPIDEMIOLOGY; HIV INFECTIONS; IMMUNOLOGY; MULTICENTER STUDY; PROSPECTIVE STUDY; TIME FACTOR; TREATMENT FAILURE; VIRUS LOAD;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4-POSITIVE T-LYMPHOCYTES; COHORT STUDIES; DRUG ADMINISTRATION SCHEDULE; HIV INFECTIONS; HUMANS; PROSPECTIVE STUDIES; RNA, VIRAL; SOUTH AFRICA; TIME FACTORS; TREATMENT FAILURE; UGANDA; VIRAL LOAD;

EID: 84906935400     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000000349     Document Type: Article

References (49)

1. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. http://aidsinfo.nih.gov/ContentFiles/ Adultand.Adoles centGL.pdf. [Accessed 5 November 2013].
2. Stringer JS, Zulu I, Levy J, Stringer EM, Mwango A, Chi BH, et al. Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes. JAMA 2006; 296: 782-793.
3. Keiser O, MacPhail P, Boulle A, Wood R, Schechter M, Dabis F, et al. Accuracy of WHO CD4 cell count criteria for virological failure of antiretroviral therapy. Trop Med Int Health 2009; 14: 1220-1225.
4. Ingole N, Mehta P, Pazare A, Paranjpe S, Sarkate P. Performance of immunological response in predicting virological failure. AIDS Res Hum Retroviruses 2013; 29: 541-546.
5. Rawizza HE, Chaplin B, Meloni ST, Eisen G, Rao T, Sankale JL, et al. Immunologic criteria are poor predictors of virologic outcome: implications for HIV treatment monitoring in resource-limited settings. Clin Infect Dis 2011; 53: 1283-1290.
6. Reynolds SJ, Nakigozi G, Newell K, Ndyanabo A, Galiwongo R, Boaz I, et al. Failure of immunologic criteria to appropriately identify antiretroviral treatment failure in Uganda. AIDS 2009; 23: 697-700.
7. Westley BP, DeLong AK, Tray CS, Sophearin D, Dufort EM, Nerrienet E, et al. Prediction of treatment failure using 2010 World Health Organization Guidelines is associated with high misclassification rates and drug resistance among HIVinfected Cambodian children. Clin Infect Dis 2012; 55: 432-440.
8. WHO. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. 2010 Revision. Geneva: WHO; 2010.
9. WHO. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. Geneva: World Health Organization; 2013.
10. Hatano H, et al. Rate of viral evolution and risk of losing future drug options in heavily pretreated, HIV-infected patients who continue to receive a stable, partially suppressive treatment regimen. Clin Infect Dis 2006; 43: 1329-1336.
11. Petersen ML, van Der Laan MJ, Napravnik S, Eron JJ, Moore RD, Deeks SG, et al. Long-Term consequences of the delay between virologic failure of highly active antiretroviral therapy and regimen modification. AIDS 2008; 22: 2097-2106.
12. Johnson BA, Ribaudo H, Gulick R, Eron J. Modeling clinical endpoints as a function of time of switch to second line ART with incomplete data on switching times. Biometrics 2013; 69: 732-740.
13. Li L, Eron J, Ribaudo H, Gulick R, Johnson B. Evaluating the effect of early versus late ARV regimen change if failure on an initial regimen: results from the AIDS Clinical Trials Group study A5095. J Am Stat Assoc 2012; 107: 542-554.
14. Laurent C, Kouanfack C, Laborde-Balen G, Aghokeng AF, Mbougua JB, Boyer S. Monitoring of HIV viral loads, CD4 cell counts, and clinical assessments versus clinical monitoring alone for antiretroviral therapy in rural district hospitals in Cameroon (Stratall ANRS 12110/ESTHER): a randomised noninferiority trial. Lancet Infect Dis 2011; 11: 825-833.
15. Chang LW, Harris JE, Humphreys E. Optimal monitoring strategies for guiding when to switch first-line antiretroviral therapy regimens for treatment failure in adults and adolescents living with HIV in low-resource settings. Cochrane Database Syst Rev 2010: CD008494.
16. Mermin J, Ekwaru J, Were W, Degerman R, Bunnell R, Kaharuza F, et al. Utility of routine viral load, CD4 cell count, and clinical monitoring among adults with HIV receiving antiretroviral therapy in Uganda: randomised trial. BMJ 2011; 343: d6792.
17. Saag M, Westfall A, Luhanga D, Mulenga P, Chi B, Mulenga L. et al. A cluster randomized trial of routine vs discretionary viral load monitoring among adults starting ART: Zambia [Abstract #87]. 19th Annual Conference on Retroviruses and Opportunistic Infections; 5-8 March 2012; Seattle, WA, USA.
18. Jourdain G, Le Coeur S, Ngo-Giang-Huong N, Traisathit P, Cressey T, Fregonese F, et al. Switching HIV treatment in adults based on CD4 count versus viral load monitoring: a randomized, non-inferiority trial in Thailand. PLoS Med 2013; 10: e1001494.
19. Keiser O, Chi B, Gsponer T, Boulle A, Orrell C, Phiri S, et al. Outcomes of antiretroviral treatment in programmes with and without routine viral load monitoring in Southern Africa. AIDS 2011; 25: 1761-1769.
20. ART-LINC of IeDEA Study Group. Switching to second-line antiretroviral therapy in resource-limited settings: comparison of programmes with and without viral load monitoring. AIDS 2009; 23: 1867-1874.
21. Levison JH, Orrell C, Losina E, Lu Z, Freedberg K, Wood R. Early outcomes and the virological effect of delayed treatment switching to second-line therapy in an antiretroviral roll-out programme in South Africa. Antivir Ther 2011; 16: 853-861.
22. Robins JM, Hernan MA, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology 2000; 11: 550-560.
23. Kalbfleisch JD, Prentice RL. The statistical analysis of failure time data Wiley series in probability and statistics. Hoboken, NJ: Wiley Interscience; 2002.
24. Aalen O. Nonparametric estimation of partial transmission probabilities in multiple decrement models. Ann Stat 1978; 6: 534-545.
25. White H. A heteroskedasticity-consistent covariance-matrix estimator and a direct test for heteroskedasticity. Econometrica 1980; 48: 817-838.
26. Gsponer T, Petersen M, Egger M, Phiri S, Maathuis M, Boulle A, et al. The causal effect of switching to second-line ART in programmes without access to routine viral load monitoring. AIDS 2012; 26: 57-65.
27. Robins J. Association causation and marginal structural models. Synthese 1999; 121: 151-179.
28. van Der Laan MJ, Polley EC, Hubbard AE. Super learner. Stat Appl Genet Mol Biol 2007; 6: Article 25.
29. Kooperberg C, Bose S, Stone C. Polychotomous regression. J Am Stat Assoc 1997; 92: 117-127.
30. Kooperberg C. Polspline: Polynomial spline routines. R package version 1.1.9. 2013. http://CRAN.R-project.org/package=pols pline. [Accessed 3 June 2014]
31. Polley EC, van Der Laan M, Super learner prediction. R package version 2.0-9. 2012. http://CRAN.R-project.org/package=Super Learner. [Accessed 3 June 2014]
32. Zhou J, Li P, Kumarasamy N, Boyd M, Chen Y, Sirisanthana T, et al. Deferred modification of antiretroviral regimen following documented treatment failure in Asia: results from the TREAT Asia HIV Observational Database (TAHOD). HIV Med 2010; 11: 31-39.
33. Fox MP, Cutsem G, Giddy J, Maskew M, Keiser O, Prozesky H, et al. Rates and predictors of failure of first-line antiretroviral therapy and switch to second-line ART in South Africa. J Acquir Immune Defic Syndr 2012; 60: 428-437.
34. Johnston V, Fielding KL, Charalambous S, Churchyard G, Phillips A, Grant AD, et al. Outcomes following virological failure and predictors of switching to second-line antiretroviral therapy in a South African treatment program. J Acquir Immune Defic Syndr 2012; 61: 370-380.
35. Davies MA, Moultrie H, Eley B, Rabie H, Van Cutsem G, Giddy J, et al. Virologic failure and second-line antiretroviral therapy in children in South Africa -The IeDEA Southern Africa collaboration. J Acquir Immune Defic Syndr 2011; 56: 270-278.
36. Havlir DV, Koelsch K, Strain M, Margot N, Lu B, Ignacio C, et al. Predictors of residual viremia in HIV-infected patients successfully treated with efavirenz and lamivudine plus either tenofovir or stavudine. J Infect Dis 2005; 191: 1164-1168.
37. Gupta RK, Hill A, Sawyer A, Cozzi-Lepri A, von Wyl V, Yerly S, et al. Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-Analysis. Lancet Infect Dis 2009; 9: 409-417.
38. Geng EH, Glidden D, Bangsberg D, Bwana M, Musinguzi N, Nash D, et al. A causal framework for understanding the effect of losses to follow-up on epidemiologic analyses in clinic-based cohorts: the case of HIV-infected patients on antiretroviral therapy in Africa. Am J Epidemiol 2012; 175: 1080-1087.
39. Hernan MA, Lanoy E, Costagliola D, Robins JM. Comparison of dynamic treatment regimes via inverse probability weighting. Basic Clin Pharmacol Toxicol 2006; 98: 237-242.
40. van Der Laan MJ, Petersen ML. Causal effect models for realistic individualized treatment and intention to treat rules. Int J Biostat 2007; 3: 3.
41. Wilson D, Keiluhu A, Kogrum S, Reid T, Seriratana N, Ford N, et al. HIV-1 viral load monitoring: an opportunity to reinforce treatment adherence in a resource-limited setting in Thailand. Trans R Soc Trop Med Hyg 2009; 103: 601-606.
42. Sigaloff KC, Hamers RL, Wallis CL, Kityo C, Siwale M, Ive P, et al. Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. J Acquir Immune Defic Syndr 2011; 58: 23-31.
43. Kantor R, Diero L, Delong A, Kamle L, Muyonga S, Mambo F, et al. Misclassification of first-line antiretroviral treatment failure based on immunological monitoring of HIV infection in resource-limited settings. Clin Infect Dis 2009; 49: 454-462.
44. Phillips AN, Pillay D, Garnett G, Bennett D, Vitoria M, Cambiano V, et al. Effect on transmission of HIV-1 resistance of timing of implementation of viral load monitoring to determine switches from first to second-line antiretroviral regimens in resource-limited settings. AIDS 2011; 25: 843-850.
45. Phillips AN, Pillay D, Miners A, Bennett D, Gilks C, Lundgren JD. Outcomes from monitoring of patients on antiretroviral therapy in resource-limited settings with viral load, CD4 cell count, or clinical observation alone: a computer simulation model. Lancet 2008; 371: 1443-1451.
46. Kahn JG, Marseille E, Moore D, Bunnell R, Were W, Degerman R, et al. CD4 cell count and viral load monitoring in patients undergoing antiretroviral therapy in Uganda: cost effectiveness study. BMJ 2011; 343: d6884.
47. Bishai D, Colchero A, Durack DT. The cost effectiveness of antiretroviral treatment strategies in resource-limited settings. AIDS 2007; 21: 1333-1340.
48. Braithwaite RS, Nucifora K, Yiannoutsos C, Musick B, Kimaiyo S, Diero L, et al. Alternative antiretroviral monitoring strategies for HIV-infected patients in east Africa: opportunities to save more lives? J Int AIDS Soc 2011; 14: 38.
49. Estill J, Aubriere C, Egger M, Johnson L, Wood R, Garone D, et al. Viral load monitoring of antiretroviral therapy, cohort viral load and HIV transmission in Southern Africa: a mathematical modelling analysis. AIDS 2012; 26: 1403-1413.